# A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy

Source: https://onco.cc/trials/nct06126640/  
OnCo record `nct06126640` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Trastuzumab rezetecan and Trastuzumab emtansine in HER2-positive breast cancer, run by Jiangsu HengRui Medicine Co., Ltd., active and no longer recruiting.

## Summary

A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy is a phase 3 interventional study registered as NCT06126640 by Jiangsu HengRui Medicine Co., Ltd., with 1615 participants enrolled, started 2023-11-20 and due to reach its primary completion in 2030-04. Interventions recorded: SHR-A1811 and Trastuzumab Emtansine.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06126640
- Phase: 3
- Setting: A Phase III, Multicenter, Randomized, Open-Label, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
- Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- Enrolled: 1615

## Sources

- ClinicalTrials.gov NCT06126640: https://clinicaltrials.gov/study/NCT06126640

## Connected records

- cancers: [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/)
- drugs: [Trastuzumab emtansine](https://onco.cc/drugs/trastuzumab-emtansine/), [Trastuzumab rezetecan](https://onco.cc/drugs/trastuzumab-rezetecan/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct06126640.json